Hero

Celyad to Present Updates on CYAD-01 at the American Association for Cancer Research (AACR) Annual Meeting 2018

1

Celyad to Present Updates on CYAD-01 at the American Association for Cancer Research (AACR) Annual Meeting 2018

Celyad Reports 2017 Financial and Operating Results and Expected Key Milestones for 2018

2

Celyad Reports 2017 Financial and Operating Results and Expected Key Milestones for 2018

Celyad Provides Clinical Update and Strategic Outlook for 2018

3

Celyad Provides Clinical Update and Strategic Outlook for 2018

About Celyad

Making the Impossible Possible

Celyad is a clinical-stage biopharmaceutical that is developing next generation CAR-T NK cell-based immunotherapies for cancer treatment.

Latest News

Celyad to Present Updates on CYAD-01 at the American Association for Cancer Research (AACR) Annual Meeting 2018

Celyad to Present Updates on CYAD-01 at the American Association for Cancer Research (AACR) Annual Meeting 2018

Celyad Reports 2017 Financial and Operating Results and Expected Key Milestones for 2018

Celyad Reports 2017 Financial and Operating Results and Expected Key Milestones for 2018

Celyad to Host Key Opinion Leader Meeting on CAR-T Therapy for the Treatment of Blood Cancers

Celyad to Host Key Opinion Leader Meeting on CAR-T Therapy for the Treatment of Blood Cancers

Discover all news

Carousel

Social Feed

Interview of @ChristianHomsy, CEO @CelyadSA : “This is the First Time CAR-T Has Ever Worked on Acute Myeloid Leukem… https://t.co/RTHINhYy8p

14 minutes ago

Interview of @ChristianHomsy, CEO @CelyadSA : “This is the First Time CAR-T Has Ever Worked on Acute Myeloid Leukem… https://t.co/RTHINhYy8p

Interview of our CFO, Patrick Jeanmart @LaBourseEtLaVie https://t.co/26BDpo3QK4

5 hours ago

Interview of our CFO, Patrick Jeanmart @LaBourseEtLaVie https://t.co/26BDpo3QK4

Celyad's novel CAR T-cell therapy for solid malignancies https://t.co/pcNEmf9qDS https://t.co/zuW98UY650

6 days ago

Celyad's novel CAR T-cell therapy for solid malignancies https://t.co/pcNEmf9qDS https://t.co/zuW98UY650

RT @EdisonHealth: Client company @CelyadSA presenting at HC Wainwright conference $CYAD #CART #HCW18 https://t.co/A8MiFOOFef

1 week ago

RT @EdisonHealth: Client company @CelyadSA presenting at HC Wainwright conference $CYAD #CART #HCW18 https://t.co/A8MiFOOFef

Interview of @ChristianHomsy, CEO @CelyadSA : “This is the First Time CAR-T Has Ever Worked on Acute Myeloid Leukem… https://t.co/RTHINhYy8p

14 minutes ago

Interview of @ChristianHomsy, CEO @CelyadSA : “This is the First Time CAR-T Has Ever Worked on Acute Myeloid Leukem… https://t.co/RTHINhYy8p

Interview of our CFO, Patrick Jeanmart @LaBourseEtLaVie https://t.co/26BDpo3QK4

5 hours ago

Interview of our CFO, Patrick Jeanmart @LaBourseEtLaVie https://t.co/26BDpo3QK4

Celyad's novel CAR T-cell therapy for solid malignancies https://t.co/pcNEmf9qDS https://t.co/zuW98UY650

6 days ago

Celyad's novel CAR T-cell therapy for solid malignancies https://t.co/pcNEmf9qDS https://t.co/zuW98UY650

RT @EdisonHealth: Client company @CelyadSA presenting at HC Wainwright conference $CYAD #CART #HCW18 https://t.co/A8MiFOOFef

1 week ago

RT @EdisonHealth: Client company @CelyadSA presenting at HC Wainwright conference $CYAD #CART #HCW18 https://t.co/A8MiFOOFef